

## 1 Supplementary Materials

### 2 **The “vaccinatable” population and doses requiring a decision**

3 Assume that we have  $D$  vaccine doses for deployment. In order to consider our question of  
4 deploying vaccine doses as first or second doses we only wish to model the impact of those  
5 fraction of the doses that we actually have a choice to deploy as second doses. I.e. if  $k$   
6 individuals have received a first dose, and have not yet been infected, and  $k < D$ , then only  $k$   
7 of our total doses  $D$  require a decision of deploying as a first or second dose. On the other  
8 hand, if  $k \geq D$ , then we can choose to deploy all of our doses as second doses. Thus, we only  
9 consider the doses of vaccine for which a deployment decision is required, (we call this  
10 quantity  $d = \min(k, D)$ ).

11 Therefore, for the vaccine doses,  $d$  we can either deploy them to a group of  $d$  people who  
12 have already received 1 dose (and who we assume have not been infected, call this  
13 population,  $N_1 = d$ ), or a different group of  $d$  people who have not received a first dose (call  
14 this population,  $N_0 = d$ ). Therefore, we define the “vaccinatable” individuals as these  $N_1 +$   
15  $N_0 = 2d$  individuals in our total population to whom we could choose to deploy our  $d$   
16 vaccine doses (either as a first dose or a second dose). We assume that the individuals with 1  
17 dose already ( $N_1$ ) received their first dose  $s$  weeks before the current vaccine deployment  
18 decision of interest and that  $s$  is at least 4 weeks (given the MVA-BN vaccine schedule  
19 recommends a second dose not earlier than 4 weeks after the first).

### 20 **Generalising the comparison of one and two dose strategies when the force of infection** 21 **is not constant with time.**

22 Within our analysis we calculate the expected number of cases that occurs within the  
23 vaccinatable population ( $d$ ). This analysis used a constant force of infection to model the case  
24 numbers and the resulting ratio of cases averted is given by (methods equation 3),

$$25 \quad RCA(t) = \frac{CA_1(t)}{CA_2(t)} = \frac{\int_0^t VE_1(x)dx + \int_0^t VE_1(x + s)dx}{\int_0^t VE_{2,s}(x)dx}. \quad (1)$$

26 This quantity translates to the ratio of the average vaccine effectiveness across a group of  
27 people (unvaccinated individuals contribute 0 to average effectiveness).

28 Applying a more sophisticated model, we can model case numbers when the infection rate  
29 varies with time. That is, consider an unvaccinated susceptible population,  $S_u$ , with a varying  
30 rate of exposure over time. The number of susceptible unvaccinated individuals over time,  $t$ ,  
31 is described by,

$$\frac{dS_u}{dt} = -r(t)S_u, \quad (2)$$

32

33 where  $r(t)$  is the infection rate at time,  $t$ . Here we ignore effects of individuals becoming  
34 susceptible again (i.e. we assume infected individuals acquire a high level of immunity for  
35 the duration of our analysis). Similarly, for a susceptible vaccinated population,  $S_v$ , we  
36 describe this rate of infection being reduced by one minus the vaccine effectiveness (VE),  
37 and so the number of vaccinated, susceptible individuals is described by,

$$\frac{dS_v}{dt} = -(1 - VE(t))r(t)S_v. \quad (3)$$

38

39 Solving, equations (2) and (3) we find that the number of unvaccinated and vaccinated  
40 susceptible individuals at a time  $t$  are given by,

$$S_u(t) = S_u(0)e^{-\int_0^t r(\lambda)d\lambda} \quad (4)$$

41 and

$$S_v(t) = S_v(0)e^{-\int_0^t r(\lambda)(1-VE(\lambda))d\lambda} = S_v(0)e^{-\int_0^t r(\lambda)d\lambda}e^{\int_0^t r(\lambda)VE(\lambda)d\lambda} \quad (5)$$

42 respectively.

43 Therefore, the total number of cases that have occurred between time  $t = 0$  and time  $t$  in the  
44 unvaccinated and vaccinated populations are given by,

$$I_u(t) = S_u(0) - S_u(t) = S_u(0)\left(1 - e^{-\int_0^t r(\lambda)d\lambda}\right) \quad (6)$$

45 and

$$I_v(t) = S_v(0) - S_v(t) = S_v(0)\left(1 - e^{-\int_0^t r(\lambda)d\lambda}e^{\int_0^t r(\lambda)VE(\lambda)d\lambda}\right) \quad (7)$$

46 respectively.

## 47 **The deployment strategies**

48 We now consider three scenarios

49 i. Baseline reference scenario

50 First, as a reference, we consider a scenario of a naïve population. Under this scenario a  
51 group of  $2d$  naïve individuals are exposed to the force of infection  $r(t)$ . Thus, from equation  
52 (6) above, and noting that in our case we have  $S_u(0) = S_v(0) = 2d$ , the total number of  
53 cases by time  $t$  is given by,

$$I_{base}(t) = 2d\left(1 - e^{-\int_0^t r(\lambda)d\lambda}\right) \quad (8)$$

54 ii. Two dose scenario

55 Under this scenario, the doses  $d$  are deployed to the group  $N_1$  as second doses. This provides  
56 these individuals with the VE of two doses, but provides individuals in the group  $N_0$  with no  
57 protection. The second dose is administered at the time of the decision point  $t = 0$  and the  
58 vaccine effectiveness of this group is given by  $VE_{2,s}(t)$ , where  $s$  is the space between the first  
59 and second dose (since VE is influenced by dose spacing). Thus, from equations (6) and (7)  
60 the total number of cases that will occur by time  $t$  under this scenario is given by,

$$I_{2dose}(t) = d\left(2 - e^{-\int_0^t r(\lambda)d\lambda} - e^{-\int_0^t r(\lambda)(1-VE_{2,s}(\lambda))d\lambda}\right) \quad (9)$$

61 The number of cases averted in the two dose scenario can be calculated by comparing the  
 62 total number of cases under this scenario with the number of cases under the baseline  
 63 scenario. Therefore the number of cases averted under the two dose scenario,  $CA_2(t)$ , is given  
 64 by:

$$CA_2(t) = I_{base}(t) - I_{2dose}(t) = d \left( e^{-\int_0^t r(\lambda)(1-VE_{2,s}(\lambda)) d\lambda} - e^{-\int_0^t r(\lambda)d\lambda} \right) \quad (10)$$

65

66 iii. One dose scenario

67 Finally, we consider the scenario where the  $d$  doses are deployed as first doses to the  $N_0$   
 68 group. This leaves the  $N_1$  group with the waning protection of their first dose given  $s + t$   
 69 earlier. From equation (7) it follows that the total number of cases by time  $t$  under this  
 70 scenario is given by,

$$I_{1dose}(t) = d \left( 2 - e^{-\int_0^t r(\lambda)(1-VE_1(\lambda)) d\lambda} - e^{-\int_0^t r(\lambda)(1-VE_1(\lambda+s)) d\lambda} \right) \quad (11)$$

71

72 The number of cases averted in the one dose scenario can be calculated by comparing the  
 73 total number of cases under this scenario with the number of cases under the baseline  
 74 scenario. Therefore the number of cases averted under the one dose scenario,  $CA_1(t)$ , is given  
 75 by:

$$\begin{aligned} CA_1(t) &= I_{base}(t) - I_{1dose}(t) \quad (12) \\ &= d \left( e^{-\int_0^t r(\lambda)(1-VE_1(\lambda)) d\lambda} + e^{-\int_0^t r(\lambda)(1-VE_1(\lambda+s)) d\lambda} \right. \\ &\quad \left. - 2e^{-\int_0^t r(\lambda)d\lambda} \right). \end{aligned}$$

76

77 Under the above scenarios we have calculated the cases averted using either the one or two  
 78 dose vaccination strategy. To simplify these relationships further, we now make first order  
 79 approximation of the exponential terms in equations (10) and (12). This first order  
 80 approximation assumes that the total force of infection over the relevant time interval is small  
 81 (in an unvaccinated cohort is small – i.e.  $\int_0^t r(\lambda) d\lambda \ll 1$ , which is akin to an assumption of  
 82 rare events – of note, since VE is between 0 and 1, it follows that  $\int_0^t r(\lambda)VE(\lambda) d\lambda <$   
 83  $\int_0^t r(\lambda) d\lambda \ll 1$ ). Under this assumption second order and larger terms in the Taylor  
 84 expansion of an exponential function, given by,

$$e^x = 1 + x + \frac{x^2}{2!} + \frac{x^3}{3!} + \dots$$

86 will be very small and thus, we assume,

$$e^{-\int_0^t r(\lambda)(1-VE_{2,s}(\lambda)) d\lambda} \approx 1 - \int_0^t r(\lambda) (1 - VE_{2,s}(\lambda)) d\lambda$$

87

88 
$$e^{-\int_0^t r(\lambda)VE_1(\lambda+s) d\lambda} \approx 1 - \int_0^t r(\lambda)(1 - VE_1(\lambda + s)) d\lambda$$

89 
$$e^{-\int_0^t r(\lambda)VE_1(\lambda) d\lambda} \approx 1 - \int_0^t r(\lambda)(1 - VE_1(\lambda)) d\lambda$$

90 and

91 
$$e^{-\int_0^t r(\lambda) d\lambda} \approx 1 - \int_0^t r(\lambda) d\lambda.$$

92 Substituting these approximations into equations (10) and (12) gives,

$$CA_2(t) = d \left( \int_0^t r(\lambda) (VE_{2,s}(\lambda)) d\lambda \right) \quad (13)$$

93

94 and

$$CA_1(t) = d \left( \int_0^t r(\lambda)(VE_1(\lambda + s))d\lambda + \int_0^t r(\lambda)(VE_1(\lambda)) d\lambda \right). \quad (14)$$

95

96 It is clear from the above that the ratio of cases averted (equations 13 and 14) will not be  
 97 independent of the force of infection, as was the case when the force of infection was  
 98 constant (main text). However, instead we can look at the difference in cases averted in these  
 99 two cases,

$$\begin{aligned} CA_1(t) - CA_2(t) & \quad (15) \\ &= d \left( \int_0^t r(\lambda)(VE_1(\lambda + s))d\lambda + \int_0^t r(\lambda)(VE_1(\lambda)) d\lambda \right. \\ & \quad \left. - \int_0^t r(\lambda) (VE_{2,s}(\lambda)) d\lambda \right). \end{aligned}$$

100 Therefore, it follows that for the cases averted by the one dose strategy to be greater than the  
 101 two dose strategy we require that,

$$\begin{aligned} CA_1(t) - CA_2(t) & \quad (16) \\ &= d \left( \int_0^t r(\lambda)VE_1(\lambda) d\lambda + \int_0^t r(\lambda)VE_1(\lambda + s) d\lambda \right. \\ & \quad \left. - \int_0^t r(\lambda)VE_{2,s}(\lambda) d\lambda \right) > 0 \end{aligned}$$

102 and this can only be true when

$$\left( \int_0^t r(\lambda)VE_1(\lambda) d\lambda + \int_0^t r(\lambda)VE_1(\lambda + s) d\lambda - \int_0^t r(\lambda)VE_{2,s}(\lambda) d\lambda \right) > 0, \quad (17)$$

103

104 since  $d > 0$ . Combining these integrals, we see that we require that

$$\left( \int_0^t r(\lambda) \left( VE_1(\lambda) + VE_1(\lambda + s) - VE_{2,s}(\lambda) \right) d\lambda \right) > 0. \quad (18)$$


105 We notice that under the strict condition that  $VE_1(\lambda) + VE_1(\lambda + s) - VE_{2,s}(\lambda) > 0$  for all  
 106  $0 < \lambda < t$ , equation (18) will hold true. Thus, rearranging this expression, we see that the one  
 107 dose strategy will avert more cases than the 2 dose strategy if the ratio (which we call the  
 108 vaccine effectiveness of the vaccinatable population, RVE),

$$RVE(t) = \frac{VE_1(t) + VE_1(t + s)}{VE_{2,s}(t)} > 1, \quad (19)$$

109 at all time-points in our time interval of interest (2 years in the main text).

110 In the same way the cases averted by the two dose strategy will be greater than the one dose  
 111 when the ratio  $RVE(t) < 1$  at all time-points.

112 Importantly, this ratio is greater than 1 at all time points for the MVA-BN vaccine regimens  
 113 we are considering (figure S1). Therefore, our result that more cases will be averted by  
 114 administering limited vaccine doses as first doses to as many individuals as possible rather  
 115 than as second doses to those already vaccinated in the main text holds independently of  
 116 assumptions of a constant force of infection.



117

118 **Figure S1:** The ratio of vaccine effectiveness at each time point,  $RVE(t)$ , from equation (19)  
 119 when the space between doses is,  $s$ , 4 weeks. Since this ratio is always greater than 1 over the  
 120 2 year period of interest, it follows (as described above) that a one-dose vaccination strategy  
 121 will avert more cases than a two dose strategy, given limited vaccine supply. Note that the  
 122 same result holds whether the spacing of doses is 6 months or 1 year (not shown).

123

124 **Considering a time varying force of infection along with different risks of infection or**  
 125 **severe outcomes**

126 Finally, we consider the case of a time varying force of infection and two groups with  
 127 different force of infection. We assume the force of infection in the high risk group is given  
 128 by  $r_h(t) = r_h h(t)$  and the risk in the low risk group is given by  $r_l(t) = r_l h(t)$ , where  $h(t)$  is  
 129 the time varying component of the force of infection. Under this assumption the relative risk  
 130 between the two groups is constant over time, but the absolute force of infection for each  
 131 group is time varying. Under this assumption we see that,

$$I_{2dose}(t) = d \left( 2 - e^{-r_l \int_0^t h(\lambda) d\lambda} - e^{-r_h \int_0^t h(\lambda) d\lambda} e^{r_h \int_0^t h(\lambda) V_{E_{2,s}}(\lambda) d\lambda} \right) \quad (20)$$

and

$$I_{1dose}(t) = d \left( 2 - e^{-r_l \int_0^t h(\lambda) d\lambda} e^{r_l \int_0^t h(\lambda) V_{E_1}(\lambda) d\lambda} \right. \\ \left. - e^{-r_h \int_0^t h(\lambda) d\lambda} e^{r_h \int_0^t h(\lambda) V_{E_1}(\lambda+s) d\lambda} \right) \quad (21)$$

The difference in cases averted between these two strategies is given by,

$$CA_1(t) - CA_2(t) \\ = d \left( e^{-r_l \int_0^t h(\lambda) d\lambda} + e^{-r_h \int_0^t h(\lambda) d\lambda} e^{r_h \int_0^t h(\lambda) V_{E_{2,s}}(\lambda) d\lambda} \right. \\ \left. - e^{-r_l \int_0^t h(\lambda) d\lambda} e^{r_l \int_0^t h(\lambda) V_{E_1}(\lambda) d\lambda} \right. \\ \left. - e^{-r_h \int_0^t h(\lambda) d\lambda} e^{r_h \int_0^t h(\lambda) V_{E_1}(\lambda+s) d\lambda} \right) \quad (22)$$

Taking a first order approximation, as above, and expanding and simplifying we find that

$$I_{1dose}(t) - I_{2dose}(t) \\ \approx d \left( r_l \int_0^t h(\lambda) V_{E_1}(\lambda) d\lambda + r_h \int_0^t h(\lambda) V_{E_1}(\lambda + s) d\lambda \right. \\ \left. - r_h \int_0^t h(\lambda) V_{E_{2,s}}(\lambda) d\lambda \right). \quad (23)$$

132

133 Thus, as above  $I_{1dose}(t) - I_{2dose}(t) > 0$  only when,

$$\int_0^t h(\lambda) \left( r_l V_{E_1}(\lambda) + r_h V_{E_1}(\lambda + s) - r_h V_{E_{2,s}}(\lambda) \right) d\lambda > 0. \quad (24)$$

134 Equation (24) will be satisfied whenever

$$r_l V_{E_1}(\lambda) + r_h V_{E_1}(\lambda + s) - r_h V_{E_{2,s}}(\lambda) > 0 \quad (24)$$

135 for all  $0 < \lambda < t$ .

136 Thus, the one dose strategy will avert more cases than the 2 dose strategy whenever,

$$\frac{r_h}{r_l} > \frac{VE_1(t)}{VE_{2,s}(t) - VE_1(t + s)} \quad (25)$$

137 for time points in our analysis. From this we see that in the case of a time varying force of  
138 infection, we can define a critical relative risk threshold between high risk and low risk  
139 individuals, such that when the ratio in equation 25 is satisfied, we can be confident the one  
140 dose-strategy is superior. This proof leaves open the possibility that even in some cases  
141 where equation (25) is not satisfied, the one-dose strategy may be optimal.